- Previous Close
24.15 - Open
23.90 - Bid 22.55 x --
- Ask 22.70 x --
- Day's Range
23.90 - 23.90 - 52 Week Range
21.75 - 35.44 - Volume
0 - Avg. Volume
0 - Market Cap (intraday)
635.663M - Beta (5Y Monthly) 1.48
- PE Ratio (TTM)
34.64 - EPS (TTM)
0.69 - Earnings Date Apr 29, 2025
- Forward Dividend & Yield 0.40 (1.62%)
- Ex-Dividend Date Apr 11, 2025
- 1y Target Est
--
Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, rest of Europe, North America, and internationally. The company offers iCare IC100 and IC200 tonometers; iCare HOME, a device for self-measurement of eye pressure; and iCare TONOVET an IOP measuring on animal patients by general veterinary practitioners, veterinary ophthalmologists, and other veterinary medical personnel. It also provides imaging devices comprising iCare EIDON AF, a device with confocal retinal imaging; and DRSplus, a device for pupil imaging; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images. In addition, the company offers Oculo, an eye care software platform, which combines clinical communication, telehealth, remote patient monitoring and data analytics capabilities. Revenio Group Oyj was incorporated in 2001 and is based in Vantaa, Finland.
www.reveniogroup.fiRecent News: R0V.MU
View MorePerformance Overview: R0V.MU
Trailing total returns as of 4/11/2025, which may include dividends or other distributions. Benchmark is OMX Helsinki_PI (^OMXHPI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: R0V.MU
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: R0V.MU
View MoreValuation Measures
Market Cap
629.01M
Enterprise Value
621.11M
Trailing P/E
34.84
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.22
Price/Book (mrq)
5.96
Enterprise Value/Revenue
6.00
Enterprise Value/EBITDA
20.37
Financial Highlights
Profitability and Income Statement
Profit Margin
17.82%
Return on Assets (ttm)
11.42%
Return on Equity (ttm)
17.82%
Revenue (ttm)
103.82M
Net Income Avi to Common (ttm)
18.5M
Diluted EPS (ttm)
0.69
Balance Sheet and Cash Flow
Total Cash (mrq)
20.69M
Total Debt/Equity (mrq)
11.87%
Levered Free Cash Flow (ttm)
17.53M